RNXT.US RenovoRx Inc

Healthcare Biotechnology USA Stocks
0.9549 USD
Close of Nov 17, 2026
0.7550 2.59
Market cap
USD 46.1M
P/E
-
P/B
5.43x
ROE
-144.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RNXT.US undervalued?

Graham number

The Graham number of RenovoRx Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RenovoRx Inc fundamental analysis

No fundamental analysis for RenovoRx Inc yet.

RenovoRx Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RenovoRx Inc

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Full company profile